Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation
Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.
You may also be interested in...
President Trump has directed his new HHS Secretary to bring down drug prices – starting 2018 exactly the same way as 2017. But this time it could end differently.
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.